Gestational surrogacy in the Czech Republic by Rumpík, David et al.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Jun; 163(2):155-160.
155
Gestational surrogacy in the Czech Republic
David Rumpika,b, Tatana Rumpikovaa,c, Michal Pohankab, Pavel Ventrubab, Silvie Belaskovad
Background. Gestational surrogacy, is a treatment option for women with certain clearly defined medical problems, 
usually an absent uterus, to help them have their own genetic children. The aim of our study was to review, evaluate 
and share our experience and outcomes over the last 13 years of the largest surrogacy program in the Czech republic.
Methods. A total of 75 intended mothers and 82 surrogate mothers participated in this study. A retrospective cohort 
study was performed. Anonymized data were collected on 130 cycles of gestational surrogate (2004-2017) directly 
from the Clinic database. 
Results. We performed 130 in vitro fertilization cycles with gestational surrogacy which involved 73 fresh embryo 
transfers and 57 frozen embryo transfers. We achieved 57 (43.9%) pregnancies and 42 (32.3%) live births. The rate of 
multiple pregnancies was only 2.3 %. The most common indication for using was an absent or damaged uterus (65%), 
followed by medical conditions precluding pregnancy (23%) and repeated in vitro fertilization cycles or pregnancy 
failure (12%).
Conclusion. In the 14 years of our experience, we have shown that treatment of young women with specific indica-
tions for gestational surrogacy is beneficial, successful and relatively free of complications. However, it is imperative 
to follow the medical indications for this treatment and specialist recommendations.
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INTRODUCTION
Gestational surrogacy, whereby the child is conceived 
using the egg of an intended mother and the sperm of an 
intended father and the resulting embryo is transferred to 
the uterus of a surrogate mother, is a recent phenomenon. 
It was introduced only after the first in vitro child was 
born. Introduction of egg donation in 1983 in particular 
paved the way for this form of surrogacy1. The first suc-
cessful gestational surrogate pregnancy involving in vitro 
assisted reproductive technology (ART) was reported by 
Utian et al. in 1985 (ref.2). 
Gestational surrogacy (GS), otherwise known as “In 
vitro fertilisation (IVF) surrogacy“ or “full surrogacy“ is a 
treatment option for women with certain clearly defined 
medical problems to help them have their own genetic 
children3. The indications for treatment by GS have in-
volved over time. When surrogacy programs were initi-
ated, the prime indication for GS was for women who had 
had a hysterectomy2,4,5. It was later became apparent that 
success also could be achieved for women with Mayer-
Rokitansky-Küster-Hauser syndrome6,7. Afterwards, wom-
en with repeated IVF failures and those with recurrent 
abortions were also considered suitable for treatment by 
GS (ref.8). With increasing experience and use of GS as a 
treatment option, the number of indications has increased 
over the last 30 years9. Women suffer from severe medi-
cal conditions that would cause childbearing to threaten 
the health or life of the recipient are also indicated for 
the use of GS. The largest reported series from Canada 
reviewed the outcomes of 333 consecutive GS cycles car-
ried out between 1998 and 2012. They list thirty specific 
medical indications for GS (ref.10). The most significant 
recent addition to the indications for surrogacy has been 
for same-sex male couples who wish to have families of 
their own11. In the Czech Republic current law prohibits 
ART including surrogacy for same-sex couples12.
Treatment by GS involves routine IVF procedures for 
the intended mother, with the transfer of fresh or frozen-
thawed embryos to the surrogate host. Surrogate mother 
(SM) is a woman who carries and delivers a child for 
another couple and who agrees that the child can be ad-
opted. Thus surrogate hosts the pregnancy but does not 
have a genetic connection to the child1.
The results of treatment using GS are good, clinical 
pregnancy rates achieved in large series are up to 40% 
per transfer3.
But surrogacy is not without its difficulties. From the 
medical point of view, this is not a complicated treatment, 
but from an ethical, legal and social point of view, it is the 
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most controversial form of assisted reproduction, with a 
number of pitfalls for intended parents, surrogate mother, 
and last but not least for the child13.
Although uncommon, the SM may change her mind 
and decide to keep the child. Intended parents (IPs) may 
also change their mind and the child might be abandoned 
by them in the case of unexpected complications or birth 
defects. In many Western countries surrogacy practice has 
been made illegal because of concern for the SM. There 
have been worries about the possibility of exploitation or 
coercion of women to act as gestational carriers14,15. 
The most important concern related to surrogacy 
treatment is anxiety about possible harmful medical and 
psychological consequences for the child. A large sys-
tematic review has shown that the perinatal outcome of 
the children is comparable to standard IVF and oocyte 
donation and there is no evidence of harm to the chil-
dren born as a result of surrogacy16. The findings from 
the studies of surrogacy that currently exist, indicate that 
families formed in this way are generally functioning well, 
suggesting that the absence of a gestational link between 
the parents and the child does not jeopardize the devel-
opment of positive family relationships or positive child 
adjustment17-21. 
Our clinic has been dealing with GS since 2004. In 
the Czech Republic surrogacy is not regulated by law but 
also not prohibited. In 2012, the Committee for Assisted 
Reproduction (CAR) of the Czech Gynaecological and 
Obstetrical Society approved the guidelines according to 
which individual IVF centers should proceed in the treat-
ment of infertility with the use of surrogacy22. Surrogacy 
is an ART procedure reserved for medical indications 
only. For social reasons it is unacceptable. In accordance 
with the recommendations of an International Federation 
of Gynecology & Obstetrics (FIGO) Committee report, 
only gestational surrogacy is acceptable at this time. The 
autonomy of the SM should be respected at all stages, 
including any decision about her pregnancy, which 
may conflict with the commissioning couple’s interest. 
Surrogacy arrangements should not be commercial. The 
choice of the SM is of the highest importance for the 
successful outcome of the treatment16. To minimize the 
medical risks to the SM, criteria were established which 
follows the latest recommendations drawn up by specialist 
groups in ESHRE, ASRM and FIGO (ref.23-25). To avoid 
unnecessary endangerment of the health of the surrogate 
and the future child it is strongly recommended that only 
one embryo at a time is transferred to the surrogate23. 
A legal contract signed by all parties after obtaining inde-
pendent legal advice, a thorough psychosocial assessment 
and counselling regarding all types of issues is essential 
and is mandatory in our program. 
The purpose of our study was to evaluate and share our 
experience over the last 14 years with 130 GC cycles that 
were performed in the Clinic of Reproductive Medicine 
and Gynecology in Zlin. This represents, to our knowl-
edge, the largest GS program in the Czech Republic.
MATERIALS AND METHODS
Subjects
A total of 75 intended mothers and 82 surrogate moth-
ers participated in this study. A retrospective cohort study 
was performed. Anonymized data were collected regard-
ing 130 cycles of gestational surrogate (2004-2017) direct-
ly from the IVF Clinic database. This study was approved 
by the Ethics Committee of the IVF Clinic.
The intended parents are responsible for recruitment 
of surrogate mothers. The IVF clinic has never been 
involved in this process. All surrogate mothers were ex-
amined and consulted according to CAR (Committee 
of Assisted Reproduction) recommendations22. A cycle 
coordination was achieved by the use of GnRH analogue. 
Surrogate mother receptivity preparation is carried out 
using oral estradiol to build up the endometrial lining, fol-
lowed by progesterone administered by vaginal capsules. 
Embryo transfer was carried out 5 days after oocyte re-
trieval. Ovarian stimulation of the intended mother before 
oocyte retrieval was performed using a short protocol with 
GnRH antagonists. 
Statistical analysis
Data from 130 IVF were analyzed for 73 fresh embryo 
transfers and 57 frozen embryo transfers. Categorical vari-
ables were expressed as number (n) and percentage of 
occurrence (%). Continuous variables were expressed as 
means ± standard deviation (SD). Odds ratio and Fisher 
exact test were computed to estimate the association of 
two binary variables and Pearson chi-square test was used 
to test association for a non-binary categorical variable. 
The significance level for hypothesis rejecting was 0.05 
and statistical software SAS 9.3 (SAS Institute Inc., Cary, 
NC, USA) was used for all analysis and graphs.
RESULTS
We performed 130 IVF cycles with GS which involved 
73 fresh embryo transfers and 57 frozen embryo transfers. 
We defined a cycle as a transfer of fresh or frozen-thawed 
embryo into the uterus of the surrogate mother. Our study 
included 75 intended mothers and 82 surrogate mothers. 
The difference between the number of intended moth-
ers and surrogate mothers was due to the fact that some 
intended mothers underwent treatment using GS repeat-
edly with more than one surrogate mother to achieve 
pregnancy. Of these 130 cycles, we achieved 57 (43.9%) 
pregnancies, 15 resulted in a miscarriage (11.5%) and 42 
(32.3%) resulted in a live birth. As is shown in Table 1, no 
statistically significant differences in results were found 
between fresh embryo transfer and frozen-thawed embryo 
transfer. The rate of multiple pregnancies was only 2.3% 
in our study. The elective single-embryo transfer (eSET) 
took place in our program in the last 7 years.
The indications for a GC were divided into three 
groups. Group 1 included the women without a uterus or 
with uterine damage (Table 2). This group consisted of 
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Table 1. Pregnancy, miscarriage and live birth rates in our gestational surrogacy program. 






Fresh embryo transfer 73 34 (46.57) 26 (35.62) 8 (10.95)
Frozen-thawed embryo transfer 57 23 (40.35) 16 (28.07) 7 (12.28)
Total 130 57 (43.85) 42 (32.31) 15 (11.53)
odds ratio (95% CI) fresh vs frozen  1.29 (0.64; 2.60) 1.42 (0.67; 3) 0.88 (0.3; 2.59)
P  0.593 0.45 1
Odds Ration and 95% confidence interval is estimated. 
Table 2. Distribution of the ET+KET, pregnancy, delivery and abortion grouped based on the diagnose.
Medical indications for GS n Total 
ET+KET
Pregnancy Delivery Abortion
 P   0.846 0.955 0.748
Group 1:       
 Mayer-Rokitansky-Küster-Hauser syndrome  13 27 10 8 2
 Hysterectomy for cervical carcinoma 9 17 8 5 3
 Hysterectomy for postpartum bleeding 9 12 5 4 1
 Hysterectomy for hypochromic anaemia 1 2 1 1 0
 Hysterectomy for teratoma 1 1 1 1 0
 Hysterectomy for postpartum sepsis 1 1 0 0 0
 Hysterectomy for hematometer 1 1 1 1 0
 Hysterectomy for myomatosis 3 7 2 1 1
 Hysterectomy for pelveoperitonitis 1 2 1 1 0
 Hysterectomy for adenomyosis and metrorrhagia 1 2 1 1 0
 Status after repeated Section Caesarea 3 7 2 1 1
 Myomatosis gravis 4 7 5 3 2
 Asherman’s syndrome  2 5 1 1 0
 Total 49 91 38 28 10
Group 2:      
 Diabetes mellitus 1 2 4 2 2 0
 Status post renal transplantation 4 5 2 1 1
 Status post hepatic transplantation 1 1 1 1 0
 Sclerosis multiplex 1 2 1 1 0
 Chronic renal disease 1 2 0 0 0
 Lupus erythematosus  2 2 1 0 1
 Immunological disease 1 3 1 0 1
 Status post treatment of breast cancer 1 1 1 0 1
 Astrocytoma brain tumour 1 3 1 1 0
 Dilated cardiomyopathy (DCM) 1 1 1 1 0
 Testicular feminization syndrome 1 1 1 1 0
 Rh incompatibility 1 2 1 1 0
 Total 17 27 13 9 4
Group 3:      
 Unsuccessful repeated IVF 2 4 1 1 0
 Repeated pregnancy failure 7 8 5 4 1
 Total 9 12 6 5 1
Group 1 consists of patients without uterus or with uterine damage. Group 2 consists of patients that have disease with contraindication of 
pregnancy. Group 3 consists of repeated failure IVF or repeated pregnancy failure. Pearson chi-square tests were used to compare relationships 
between group
In line with the recommendations of the CAR all surrogate mothers were at least one child in our study22. More than half of them were under the 
age of 30 years (n=42, 51.2%). The basic characteristic of the SMs are shown in Table 3.
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49 patients (mean age 35.16; SD=4.46) who completed 
91 embryo transfers. Hysterectomy was the most com-
mon indication for using a GC (27 cases), followed by 
MRKH syndrome (13 cases), myomatosis gravis (4 cas-
es), status post repeated Caesarean section (3 cases) and 
Asherman’s syndrome (2 cases). Reasons for hysterec-
tomy are listed in the Table 2. In this group, we achieved 
41.8% clinical pregnancy rate (CPR) and 30.8% live birth 
rate (LBR) per embryo transfer (no cases involved oocyte 
donors).
Group 2 included the women with medical conditions 
precluding pregnancy. This group consisted of 17 patients 
(mean age 33.35; SD=5.06) with different diseases. A list 
of all diagnoses are summarized in table 2. We performed 
27 embryo transfers in this group, in two cases we used 
oocytes from an oocyte donor (breast cancer, testicular 
feminization syndrome). 48.1% CPR and 33.3% LBR per 
transfer were achieved.
Group 3 included repeated IVF failure or repeated 
pregnancy failure. This group involved only 9 patients 
(mean age 38.67; SD=4.03) who underwent 12 embryo 
transfers, in four cases we use donated oocytes. In this 
group, we had 50% CPR and 41.7% LBR per transfer.
DISCUSSION
The intended mothers
Surrogacy is a highly debated method mainly used for 
treating women with infertility caused by uterine factors16. 
For those women, it is often a tremendous opportunity 
for family building.
Satisfactory pregnancy and delivery rates per IP and 
per SM are generally being achieved, as would be expected 
from the transfer of embryos derived from young women 
and transferred to fit, fertile women who are also young3. 
In GS programs, the clinical pregnancy rate per embryo 
transfer has been reported as being between 19 and 33%, 
with between 30 and 70% of the couples succeeding in 
becoming parents as a result of the arrangement4-6,10,16,26-29. 
In our study the CPR was 43.9% per embryo transfer and 
56% of the intended couples have become parents through 
this treatment. The live birth rate are comparable to con-
ventional IVF (ref.25). The newest retrospective cohort 
Table 3. The background characteristics of the surrogate mothers.
Characteristics of the SMs Groups n %
Marital status Single 38 46.3
Married 33 40.2
Divorced 11 13.4
Children 1 child 36 43.9
2 children 32 39.0
3 or more children 14 17.1
Age Age under 30 years 42 51.2
Age from 30 to 35 years 21 25.6
Age over 36 years 20 24.4
study compared clinical outcomes of IVF cycles with the 
use of GC (24,269) and non-GC IVF cycles (1,313,452). 
The highest LBR occurred when the indication for GC 
was uterine factor infertility30. 
In our study, 49 of the 75 intended mothers (65.3%) 
underwent treatment with GS due to uterine factor in-
fertility (congenital or acquired absence of a functioning 
uterus, Asherman's syndrome or significant structural 
abnormalities or uterine damage). 
The most common indication for using a GC in our 
study was hysterectomy. The loss of the uterus prior to 
having children or completing family could have a signifi-
cant adverse effect on the lives of most women4. Young 
fertile women with normally functioning ovaries might 
lose their uterus in connection with serious obstetric com-
plications, such as intra- or post-partum heavy bleeding or 
rupture of the uterus. Medical diseases of the uterus, most 
often cervical cancer or uterine leiomyoma in many cases 
with severe menorrhagia will also lead to hysterectomy 
and uterine infertility. A UK series, in which all the female 
partners of the intended couples had had a hysterectomy, 
achieved a CPR 37.5% per embryo transfer4. We had 27 
patients after hysterectomy, they underwent 45 stimula-
tion cycles, including fresh and frozen embryo transfers 
with GS, 15 newborns (only singletons) were delivered. 
We achieved 44.4% (20/45) CPR and 33.3% (15/45) LBR 
per embryo transfer. 
Patients with MRKH syndrome lack a functional uter-
us at birth. But when treated by IVF and GS they have 
a fair chance of achieving a live birth. Recently a com-
prehensive review of published research was conducted, 
on the reproductive potential of patients with MRKH 
syndrome using IVF with GS (ref.7). The 14 studies in-
cluded in this review were published between 1988 and 
2011. From a cohort of 140 patients with MRKH syn-
drome, only four studies contained data on more than 
10 patients26,28,31,32. The available data from these stud-
ies allowed the following calculations to be made: 22.7% 
CPR and 18% LBR per transfer. In our study 13 patients 
with MRKH underwent 27 cycles of IVF with GS and 9 
newborns were delivered (in one case twins). We achieved 
37% (10/27) CPR and 29.6% (8/27) LBR per transfer. 
As patients with MRKH syndrome have no alternative 
but to conceive using assisted reproduction techniques, 
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they will seek treatment at a relatively young age7. That 
could explain why patients with MRKH syndrome were 
the youngest group in our series; mean age 31.9 year. 
Until recently, successful transplantation of a uterus 
to a woman with MRKH syndrome or who had had a 
hysterectomy was an aspiration and dream that, despite 
attempts by many researchers over the years, had not been 
successful. However Brännström et al. in 2015 reported 
the first birth of a healthy baby following uterus trans-
plantation in a 35-year-old woman, using the uterus of 
a living 61-year-old woman33. This success was achieved 
after at least 11 other attempts worldwide. Even though 
several healthy children have been born from donated 
transplanted wombs and the acceptance of uterus trans-
plantation as infertility treatment for women with uterine 
factor of infertility is high, the procedure still remains in 
its infancy34. The process of uterus transplantation in not 
without its ethical controversy either. . It would be safer 
for the uterus donor to act as a surrogate rather than 
undergo the big operation that is much more extensive 
than a standard hysterectomy. This solution also would be 
more economical for society in general. In addition, the 
side effects of immune suppression in the recipient, such 
as increasing risk of infection and tumors, could be avoid-
ed. This aside, the overwhelming majority of surveyed 
women in the United Kingdom, a country which permits 
surrogacy, preferred transplantation of uterus over GS 
and adoption34. We can anticipate that when transplanta-
tion of the uterus becomes more available and successful, 
then the demand for GS will become less in the future.
But surrogacy still remains the only option for having a 
biological child for women with severe medical conditions 
where pregnancy could pose a significant health risk or 
maternal medications used to treat a disease, which are, 
or could potentially be, teratogenic.
This treatment should be provided only when the in-
tended mother is healthy enough to take care of a child 
after birth and that her life expectancy is reasonable3. We 
treated 17 patients with different medical co-morbidities 
precluding pregnancy. They underwent 27 cycles with GS 
and 10 newborns were delivered (in one case twins). We 
achieved 48.1% (13/27) CPR and 33.3% (9/27) LBR per 
transfer.
GS may be considered for couples with repeated un-
explained IVF failures despite retrieval of good-quality 
embryos or for couples with repeated miscarriages25. We 
did not have many patients with this indication. For these 
women the treatment of first choice is their own IVF with 
donated oocytes. Only 9 women with these indications 
were treated using GS and 6 newborns were delivered 
(in one case twins); 50% (6/12) CPR and 41.7% (5/12) 
LBR were achieved. Our results in this group of patients 
are comparable with the largest study on outcomes of GS 
(ref.10). They also reported 50% CPR and 34.8% LBR in 
a group of patients with recurrent implantation failure 
and previous poor pregnancy outcomes. In four of cases 
donated oocytes were used.
The surrogate mothers
Surrogacy implies that a woman becomes pregnant 
and gives birth to a child with the intention of giving the 
child away to another person or couple, commonly re-
ferred to as the intended parents23. The IPs are responsible 
for recruitment of SMs. In most cases they were found 
using the internet. In only four cases, the SM was a sister 
of intended mother in our study. 
According to the recommendations of the CAR, a SM 
should be between the age of 21 and 35 years and she 
should have at least one child. Her previous pregnancies 
must have been full-term and uncomplicated. Women, 
who have had previous adverse obstetric outcomes should 
not be accepted. The pregnancy history of the surrogate 
candidate may be more predictive of obstetric complica-
tions than her age35. In our study all SMs had at least 
one child, more than half of them were under the age 
of 30 years (n=42, 51.2%). We have no serious maternal 
complication in accordance with other studies10,16,27. This 
relatively low rate of maternal complications is consis-
tent with the fact that all SMs were multiparas and they 
had no significant complications in prior pregnancies10. 
Furthermore, as the risk of almost all maternal complica-
tions is increased by multiple pregnancies, elective single-
embryo transfer took place in our program in the last 7 
years. The rate of multiple pregnancies was 2.3% in our 
study. A systematic review reported 2.6-75% of multiple 
pregnancies in surrogacy programs16. 
One reason for regarding surrogacy as problematic and 
controversial is the risk of dispute between the surrogacy 
mother and the intended parents as to the custody of the 
child. 
We have no cases in which surrendering the child was 
problematic after birth. Surrogate mothers generally re-
port being satisfied with their experiences36. Follow-up 
studies have shown that there were no significant difficul-
ties for the SMs in handing over the children to the IPs 
and that surrogates do not suffer any long-term psycho-
logical harm10,36-39.
CONCLUSION
Gestational surrogacy offers an alternative way for 
a small group of women to have their own genetic chil-
dren. In the 14 years of our experience we have shown 
that treatment of young women with specific indications 
for treatment with GS is beneficial and relatively free of 
complications. The surrogacy program has been success-
fully implemented and has become an integral part of 
the treatment of some causes of infertility. However, it is 
imperative to follow the medical indications for this treat-
ment and follow the recommendations of expert groups. 
Careful counselling of all parties involved is essential. 
Also close cooperation between the medical, legal and 
social professionals is a prerequisite for satisfactory results 
in the vast majority of cases.
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